ArticleTalanta2024
A highly sensitive nanopore platform for measuring RNase A activity.
Article in Talanta, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- A CRISPR-Cas12a amplified RNase activity sensor powered by gold nanoparticle-barcode DNA multipliers.Materials advances · 2026Article
- A Label-Free Nanopore Biosensor for Rapid and Highly Sensitive Detection of Actinomycin in Human Serum.ACS measurement science au · 2026Article
- Nanopore Label-Free Monitoring of B-DNA and Z-DNA Conformational Transition in Real Time.ACS nano · 2026Article
- Regulation of Protein Transport in Functionalized PET Nanopores.The journal of physical chemistry. B · 2025Article
- Nanopore Detection of Small Molecules Based on Replacement and Complexation Chemical Interactions.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- Pioneering Role of Nanopore Single-Molecule Sensing in Environmental and Food Surveillance.Biosensors · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Ribonuclease A (RNase A) plays significant roles in several physiological and pathological conditions and can be used as a valuable diagnostic biomarker for human diseases such as myocardial infarction and cancer. Hence, it is of great importance to develop a rapid and cost-effective method for the highly sensitive detection of RNase A. The significance of RNase A assay is further enhanced by the growing attention from the biotechnology and pharmaceutical industries to develop RNA-based vaccines and drugs in large part as a result of the successful development of mRNA vaccines in the COVID-19 pandemic. Herein, we report a label-free method for the detection of RNase A by monitoring its proteolytic cleavage of an RNA substrate in a nanopore. The method is ultra-sensitive with the limit of detection reaching as low as 30 fg per milliliter. Furthermore, sensor selectivity and the effects of temperature, incubation time, metal ion, salt concentration on sensor sensitivity were also investigated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.